Patents Examined by Leslie A. Royds Draper
  • Patent number: 11020406
    Abstract: The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Solutex NA LLC
    Inventors: Charles Nicholas Serhan, Fernando Moreno Egea, Joan Clària Enrich
  • Patent number: 11014923
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: May 25, 2021
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • Patent number: 11007162
    Abstract: The present invention provides methods for increasing LDL particle size.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 18, 2021
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: David Karpf, Ronald M. Krauss, Yun-Jung Choi, Xueyan Wang, Francine M. Gregoire
  • Patent number: 10966989
    Abstract: A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and memantine or a pharmaceutically acceptable salt of memantine is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: April 6, 2021
    Assignee: LA PharmaTech Inc.
    Inventors: Jianmin Wang, Geping Cui
  • Patent number: 10959977
    Abstract: The present invention discloses uses of a novel phosphodiesterase 4 (PDE4) inhibitor ZL-n-91 in preparing drugs against lung cancer proliferation and metastasis. The mouse survival curves and in vitro cell experiments show that the PDE4 inhibitor ZL-n-91 can significantly inhibit the proliferation and metastasis of lung cancer cells, indicating that this PDE4 inhibitor ZL-n-91 can become an important target for the studies on anti-lung cancer proliferation and metastasis, to provide a basis for preparing drugs against lung cancer proliferation and metastasis, with promising prospect of development and application.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: March 30, 2021
    Inventors: Allan Zijian Zhao, Sijia Gong, Yan Lin, Fanghong Li, Xiaoxi Li
  • Patent number: 10946012
    Abstract: Methods of inducing tumor regression, inhibiting tumor growth, and inducing apoptosis with selective peptidomimetic inhibitors of geranylgeranyltransferase I (GGTase I), are provided. In one aspect, GGTI-2418 and its methylester GGTI-2417, increase levels of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 and induce breast tumor regression in vivo. In another aspect, GGTI-2417 inhibits the Cdk2-mediated phosphorylation of p27Kip1 at Thr187 and accumulates p27Kip1 in the nucleus.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: March 16, 2021
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Yale University
    Inventors: Said M. Sebti, Andrew D. Hamilton
  • Patent number: 10946026
    Abstract: A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and memantine or a pharmaceutically acceptable salt of memantine is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: March 16, 2021
    Assignee: LA PharmaTech Inc.
    Inventors: Jianmin Wang, Geping Cui
  • Patent number: 10898493
    Abstract: Pharmaceutical compositions containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients with Alzheimer's disease for symptoms of depression, anxiety, agitation, delusions, hallucination, irritability and sleeping disorder, are also disclosed.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: January 26, 2021
    Assignee: LA PharmaTech Inc.
    Inventors: Jianmin Wang, Geping Cui
  • Patent number: 10899756
    Abstract: The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods for treatment of neurodegenerative diseases, increasing memory or long term potentiation with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the phosphodiesterase is PDE5.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: January 26, 2021
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Donald W. Landry, Shixian Deng, Ottavio Arancio, Jole Fiorito, Andrew Wasmuth
  • Patent number: 10822336
    Abstract: Provided are novel crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6-(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and a pharmaceutically acceptable salt thereof having advantageous characteristics. [2-(1-Methyl-1H-pyrazol-4-yl)-6-(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and a pharmaceutically acceptable salt thereof provided by the present invention are excellent in stability and have satisfactory physical properties as a drug substance of a pharmaceutical product.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: November 3, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yasushi Ueda, Sagar Ramdas Amale, Manjunath Govind Bhovi
  • Patent number: 10799500
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: October 13, 2020
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei Yao, Peng Li, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • Patent number: 10781185
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 22, 2020
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Donna L. Romero, John McKearn, Michael Clare
  • Patent number: 10772890
    Abstract: The present invention relates to the use of myeloperoxidase inhibitors (MPO) inhibitors for the treatment of multiple system atrophy. The present invention also relates to the use of MPO inhibitors for the treatment of Huntington's disease. The present invention also relates to the use of MPO inhibitors for neuroprotection.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: September 15, 2020
    Assignee: AstraZeneca AB
    Inventors: Hakan Eriksson, Werner Poewe
  • Patent number: 10738048
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: August 11, 2020
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • Patent number: 10723700
    Abstract: The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: July 28, 2020
    Assignee: Incyte Corporation
    Inventors: Yongchun Pan, Wayne Han, Ganfeng Cao, Zhongjiang Jia, Jiacheng Zhou
  • Patent number: 10716768
    Abstract: The present invention provides a use of a compound to prepare a pharmaceutical composition for treating abnormal ?-amyloid aggregation mediated diseases. The compound is represented by the following formula (I): wherein A, B, R1, R2, R3, R4, R5 and R6 are defined in the specification.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: July 21, 2020
    Assignee: NATIONAL TAIWAN NORMAL UNIVERSITY
    Inventors: Guey-Jen Lee-Chen, Wenwei Lin
  • Patent number: 10668030
    Abstract: The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: June 2, 2020
    Assignee: University of Kentucky Research Foundation
    Inventors: Linda P. Dwoskin, Peter Anthony Crooks, Guangrong Zheng, Justin R. Nickell, Zheng Cao, Na-Ra Lee
  • Patent number: 10668072
    Abstract: A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: June 2, 2020
    Assignee: Loxo Oncology, Inc.
    Inventors: Mark Reynolds, Steven A. Smith
  • Patent number: 10653703
    Abstract: The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: May 19, 2020
    Assignee: Solutex NA LLC
    Inventors: Charles Nicholas Serhan, Fernando Moreno Egea, Joan Clària Enrich
  • Patent number: 10610526
    Abstract: A composition suitable for use in nicotine replacement therapy products includes a nicotine product that includes a synthetic nicotine that is substantially free of one or more contaminants and/or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of one or more of nicotine-1?-N-oxide, nicotyrine, nornicotyrine, 2?,3-bipyridyl, cotinine, anabasine, and/or anatabine. The composition further comprises one or more pharmaceutically acceptable excipients, additives and/or carriers. The nicotine replacement therapy products may include any number of such products, including transdermal nicotine delivery patches, nicotine gums, synthetic chewing tobacco, synthetic snuff, and synthetic strips (e.g., dissolvable synthetic tobacco). Additionally, a method of treating nicotine addiction includes administering a nicotine replacement composition, e.g., via a nicotine replacement therapy product, to a user.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: April 7, 2020
    Assignee: NEXT GENERATION LABS, LLC
    Inventor: Michael Arnold